243 related articles for article (PubMed ID: 33497479)
21. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
22. Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Fontanilles M; Marguet F; Beaussire L; Magne N; Pépin LF; Alexandru C; Tennevet I; Hanzen C; Langlois O; Jardin F; Laquerrière A; Sarafan-Vasseur N; Di Fiore F; Clatot F
Acta Neuropathol Commun; 2020 Nov; 8(1):179. PubMed ID: 33148330
[TBL] [Abstract][Full Text] [Related]
23. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
[TBL] [Abstract][Full Text] [Related]
24. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
25. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
26. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
27. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.
Alborelli I; Generali D; Jermann P; Cappelletti MR; Ferrero G; Scaggiante B; Bortul M; Zanconati F; Nicolet S; Haegele J; Bubendorf L; Aceto N; Scaltriti M; Mucci G; Quagliata L; Novelli G
Cell Death Dis; 2019 Jul; 10(7):534. PubMed ID: 31296838
[TBL] [Abstract][Full Text] [Related]
28. IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
Crucitta S; Pasqualetti F; Gonnelli A; Ruglioni M; Luculli GI; Cantarella M; Ortenzi V; Scatena C; Paiar F; Naccarato AG; Danesi R; Del Re M
BMC Cancer; 2024 Jan; 24(1):31. PubMed ID: 38172718
[TBL] [Abstract][Full Text] [Related]
29. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
30. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Kotecha RR; Gedvilaite E; Ptashkin R; Knezevic A; Murray S; Johnson I; Shapnik N; Feldman DR; Carlo MI; Shah NJ; Dunigan M; Huberman K; Benayed R; Zehir A; Berger MF; Ladanyi M; Tsui DWY; Motzer RJ; Lee CH; Voss MH
JCO Precis Oncol; 2022 Jul; 6():e2200012. PubMed ID: 35797508
[TBL] [Abstract][Full Text] [Related]
31. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
32. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
[TBL] [Abstract][Full Text] [Related]
33. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
[TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.
Miller AM; Szalontay L; Bouvier N; Hill K; Ahmad H; Rafailov J; Lee AJ; Rodriguez-Sanchez MI; Yildirim O; Patel A; Bale TA; Benhamida JK; Benayed R; Arcila ME; Donzelli M; Dunkel IJ; Gilheeney SW; Khakoo Y; Kramer K; Sait SF; Greenfield JP; Souweidane MM; Haque S; Mauguen A; Berger MF; Mellinghoff IK; Karajannis MA
Neuro Oncol; 2022 Oct; 24(10):1763-1772. PubMed ID: 35148412
[TBL] [Abstract][Full Text] [Related]
35. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
36. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
37. Utility of plasma cell-free DNA for
Gutierrez-Rodrigues F; Beerman I; Groarke EM; Patel BA; Spitofsky N; Dillon LW; Raffo DQ; Hourigan CS; Kajigaya S; Ferrucci L; Young NS
Haematologica; 2022 Aug; 107(8):1815-1826. PubMed ID: 34587721
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
39. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
40. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]